Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
4
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
4
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
4
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
4
×
wisconsin blog main
wisconsin top stories
biotech
clinical trials
spark therapeutics
alnylam pharmaceuticals
amgen
amicus therapeutics
cancer
cystic fibrosis
deals
diagnostics
fda
gene therapy
immunotherapy
medicare
What
drug
4
×
patients
4
×
bio
roundup
fda
market
acquisitions
advantages
albert
aren’t
bar
biggest
bourla
brings
cancer
ceo
company
crispr
developers
drugs
eisai
expect
flags
future
gamble
gene
help
higher
imminent
imports
incidence
long
lorcaserin
loss
maker
maps
marketing
measured
medco’s
medicare
Language
unset
unknown
Current search:
drug
×
patients
×
" raleigh-durham blog main "
×
" indiana blog main "
×
" san francisco blog main "
×
" texas top stories "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More